EP2621932A4 - Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c - Google Patents

Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c

Info

Publication number
EP2621932A4
EP2621932A4 EP11828123.7A EP11828123A EP2621932A4 EP 2621932 A4 EP2621932 A4 EP 2621932A4 EP 11828123 A EP11828123 A EP 11828123A EP 2621932 A4 EP2621932 A4 EP 2621932A4
Authority
EP
European Patent Office
Prior art keywords
viral infection
treating hepatitis
heterocycle compounds
tetracyclic heterocycle
tetracyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11828123.7A
Other languages
German (de)
English (en)
Other versions
EP2621932A1 (fr
Inventor
Michael P Dwyer
Kartik M Keertikar
Craig A Coburn
Hao Wu
Bin Hu
Bin Zhong
Chengren Zhang
Zhigang Dan
Ling Tong
Wensheng Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/077498 external-priority patent/WO2012040924A1/fr
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of EP2621932A1 publication Critical patent/EP2621932A1/fr
Publication of EP2621932A4 publication Critical patent/EP2621932A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11828123.7A 2010-09-29 2011-09-28 Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c Withdrawn EP2621932A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/077498 WO2012040924A1 (fr) 2010-09-29 2010-09-29 Composés hétérocycliques tétracycliques condensés et leurs méthodes d'utilisation pour le traitement de maladies virales
US201061426738P 2010-12-23 2010-12-23
PCT/CN2011/080270 WO2012041227A1 (fr) 2010-09-29 2011-09-28 Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c

Publications (2)

Publication Number Publication Date
EP2621932A1 EP2621932A1 (fr) 2013-08-07
EP2621932A4 true EP2621932A4 (fr) 2014-03-26

Family

ID=45891961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11828123.7A Withdrawn EP2621932A4 (fr) 2010-09-29 2011-09-28 Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c

Country Status (2)

Country Link
EP (1) EP2621932A4 (fr)
WO (1) WO2012041227A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CA2737601C (fr) 2009-06-11 2014-10-21 Abbott Laboratories Composes antiviraux
CA2767887A1 (fr) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Analogues du benzimidazole pour le traitement ou la prevention des infections a flavivirus
EP2550267A1 (fr) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues pour traiter ou prévenir les infections à flavivirus
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2616461A4 (fr) 2010-08-26 2014-03-26 Rfs Pharma Llc Inhibiteurs puissants et sélectifs du virus de l'hépatite c
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012283609B2 (en) 2011-07-09 2016-09-29 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis C virus inhibitors
WO2013030750A1 (fr) 2011-09-01 2013-03-07 Lupin Limited Composés antiviraux
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
WO2014082380A1 (fr) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Composés de type noyaux fusionnés utilisables en tant qu'inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques en contenant et leurs utilisations
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
WO2015089810A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
WO2015110048A1 (fr) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Composés cycliques pontés comme inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques et utilisations correspondantes
WO2016048643A1 (fr) 2014-09-26 2016-03-31 The Chemours Company Fc, Llc Organosilanes dérivés d'isocyanate
CN104478877B (zh) * 2014-10-31 2016-08-24 广东东阳光药业有限公司 制备雷迪帕韦中间体的方法
WO2017023631A1 (fr) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021928A2 (fr) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4143669B2 (ja) * 2004-02-24 2008-09-03 日本たばこ産業株式会社 ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
AU2005298412B2 (en) * 2004-10-26 2011-06-09 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
JP5179585B2 (ja) * 2007-08-29 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 四環系インドール誘導体およびその使用法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021928A2 (fr) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012041227A1 *

Also Published As

Publication number Publication date
EP2621932A1 (fr) 2013-08-07
WO2012041227A1 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
EP2621932A4 (fr) Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
EP2621931A4 (fr) Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
HK1248120A1 (zh) 用於慢性乙型肝炎病毒感染的基於酵母的治療劑
HK1191935A1 (en) Spiro compounds as hepatitis c virus inhibitors
EP2429568A4 (fr) Composés macrocycliques comme inhibiteurs du virus de l'hépatite c
HK1152620A1 (en) Anti-viral compounds to treat hcv infection hcv
EP2491033A4 (fr) Azaindazoles pour traiter une infection par le virus flaviviridae
EP2726459A4 (fr) Dérivés de sulfamoylbenzamide en tant qu'agents antiviraux contre une infection par vhb
ZA201205547B (en) Therapies for treating hepatitis c virus infection
HK1198869A1 (en) Combination treatments for hepatitis c
IL231217A0 (en) Tetracyclic heterocyclic compounds and methods of using them in the treatment of viral diseases
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
ZA201300992B (en) Combination therapy for treating hcv infection
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
EP2534150A4 (fr) Méthodes de traitement d'une infection virale
IL233899A0 (en) Macrocyclic compounds for suppression of hepatitis C virus replication
EP2532652A4 (fr) Agent therapeutique de l'hepatite c
HK1213816A1 (zh) 治療 型肝炎病毒感染的醫藥組合物
GB201203180D0 (en) Compounds for treating parvovirus infection
EP2536282A4 (fr) Procédés pour traiter l'infection
IL221399A (en) Composition for the treatment of viral diseases
IL228725A0 (en) Treatment of hepatitis c virus infection with alisporir
EP2589595A4 (fr) Agent thérapeutique contre l'infection par le hcv
GB201014736D0 (en) Treatment of hepatitis C
GB201114710D0 (en) Treatment of hepatitis c

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101ALI20140218BHEP

Ipc: C07D 493/22 20060101ALI20140218BHEP

Ipc: C07D 471/22 20060101ALI20140218BHEP

Ipc: C07D 491/22 20060101ALI20140218BHEP

Ipc: C07D 498/04 20060101AFI20140218BHEP

Ipc: A61K 31/4985 20060101ALI20140218BHEP

Ipc: C07D 471/04 20060101ALI20140218BHEP

Ipc: A61K 31/5365 20060101ALI20140218BHEP

Ipc: C07D 487/04 20060101ALI20140218BHEP

Ipc: A61P 31/14 20060101ALI20140218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140924